Abstracts tagged "outcome measures and rheumatoid arthritis (RA)"

Abstract Number: 2103 • 2012 ACR/ARHP Annual Meeting
Reliability of DAS28 in Rheumatoid Arthritis When Based On Patient Self-Assessment of Tender and Swollen Joints
Ole Rintek Madsen and Cecilie Heegaard, Department of Rheumatology/C, Copenhagen University Hospital Gentofte, Hellerup, Denmark
Background/Purpose: Clinical assessment of disease activity is a routine procedure when evaluating individual rheumatoid arthritis (RA) patients in daily practice. Swollen joint count (SJC) and…
Abstract Number: 2106 • 2012 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discrepancies in Evaluator-Reported and Patient-Reported Outcomes in U.S. Veterans with Rheumatoid Arthritis
Archana Jain¹, Rebecca Belsom¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Validated tools that incorporate evaluator and patient reported outcomes (PROs) are used for guiding therapy in patients with rheumatoid arthritis (RA). PROs used in…
Abstract Number: 2109 • 2012 ACR/ARHP Annual Meeting
Discrepancy Between Patient and Physician Global Assessments Over Time in Early Rheumatoid Arthritis
Pooneh Akhavan¹, Vivian P. Bykerk², Juan Xiong³, Janet E. Pope⁴, Boulos Haraoui⁵, J. Carter Thorne⁶, Gilles Boire⁷, Carol A. Hitchon⁸, Diane Tin⁹, Edward Keystone¹⁰ and CATCH¹¹, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁴Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada, ⁵Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁶Southlake Regional Health Centre, Newmarket, ON, Canada, ⁷Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital, Toronto, ON, Canada, ¹¹Toronto
Background/Purpose: Discrepancy between patient (PGA) and physician (MDGA) global assessments in RA can adversely affect therapeutic decisions in many cases. The purpose of this study…
Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Sofia Ramiro¹, Frederick Wolfe², David J. Harrison³, George Joseph³, David H. Collier³, Désirée van der Heijde⁴, Robert Landewé⁵ and Kaleb Michaud⁶, ¹Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, The Netherlands and Hospital Garcia de Orta, Almada, Portugal, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Amgen Inc., Thousand Oaks, CA, ⁴Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ⁶Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…
Abstract Number: 1311 • 2012 ACR/ARHP Annual Meeting
A Novel Individualized Treatment Approach in Open-Label Extension Study of Ozoralizumab (ATN-103) in Subjects with Rheumatoid Arthritis On a Background of Methotrexate
Roy Fleischmann¹, Steven De Bruyn², Christian Duby², Katrien Verschueren³, Judith Baumeister⁴, Laura Sargentini-Maier⁵, Cedric Ververken⁶ and Josefin-Beate Holz⁷, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Clinical Development, Ablynx N.V., Zwijnaarde, Belgium, ³Clinical Development, Ablynx nv, Zwijnaarde, Belgium, ⁴Department of Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁵Pharmacology, Ablynx N.V., Zwijnaarde, Belgium, ⁶Project Management, Ablynx N.V., Zwijnaarde, Belgium, ⁷Chief Medical Officer, Ablynx N.V., Zwijnaarde, Belgium
Background/Purpose: Ozoralizumab (ATN-103), a novel TNFα inhibitor, is a trivalent, bispecific Nanobody® that potently neutralises TNF and binds to human serum albumin to increase its…
Abstract Number: 1045 • 2012 ACR/ARHP Annual Meeting
Dynamic Contrast-Enhanced Magnetic Resonance Imaging of the Wrist in Rheumatoid Arthritis Patients Treated with Methotrexate, Intra-Articular Glucocorticoid and Adalimumab/Placebo
Mette Bjørndal Axelsen¹, Merete L. Hetland², Kim Hørslev-Petersen³, Kristian Stengaard-Pedersen⁴, Peter Junker⁵, Jan Pødenphant⁶, Jakob M. Møller⁷, Henning Bliddal⁸, Olga Kubassova⁹, Mikael Boesen¹⁰ and Mikkel Østergaard¹¹, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ⁴Arhus University Hospital, Aarhus, Denmark, ⁵Odense University Hospital, Odense, Denmark, ⁶Copenhagen University at Gentofte, Hellerup, Denmark, ⁷Department of Radiology, Copenhagen University Hospital in Herlev, Copenhagen, Denmark, ⁸Department of Rheumatology, The Parker Institute, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, ⁹Image Analysis Ltd., Leeds, United Kingdom, ¹⁰The Parker Institute, Department of Rheumatology, Copenhagen University Hospital at Frederiksberg, Copenhagen, Denmark, ¹¹Dept of Rheumatology RM, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Background/Purpose: To validate parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in an early rheumatoid arthritis (RA) clinical trial by comparison with clinical parameters of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.